hsa-mir-361: Hsa-mir-361 is a microRNA (miRNA) that has been implicated in various biological processes and diseases, including cancer and cardiovascular diseases [PMC8706837]. It is transcribed using specific RT primers in microRNA assays [PMC7998231], and its expression levels have been observed to be lower in tumor samples compared to normal samples [PMC8186776]. Hsa-mir-361 has not been extensively studied across different cancers, but its potential as a pan-cancer prognostic marker warrants further investigation [PMC6602415]. It is differentially expressed during pregnancy, with upregulation noted in the third trimester [PMC9700700], and significant upregulation observed in the first trimester among gestational diabetes mellitus (GDM) patients [PMC9700700]. In gastric cancer subtypes, hsa-mir-361 expression varies with tumor stage and nodal involvement [PMC4496000]. It has also been shown to enhance fusion capacity in myoblasts when overexpressed or when hsa-miR-98 is inhibited [PMC4325962]. Hsa-mir-361 serves as a protective miRNA in certain subtypes of glioblastoma multiforme (GBM) and has been used as an internal reference molecule for normalizing miRNA expression levels during quantitative RT-PCR analysis [PMC3917617], [PMC8473752], [PMC5348325]. Its expression profile differs between tumor tissue, where the 5p arm is dominant, and normal tissue where the 3p arm prevails [PMC3303722], indicating its potential involvement in disease progression as predicted by LE-MDCAP analysis tools for disease association prediction [PMC8706837].